ALENTIS THERAPEUTICS CLOSES $105 MILLION SERIES C FUNDING TO ADVANCE TRANSFORMATIONAL MEDICINES FOR CLAUDIN-1

ALENTIS THERAPEUTICS REPORTS POSITIVE TOPLINE RESULTS FROM PHASE 1 MULTIPLE-ASCENDING DOSE COHORTS STUDY